Women diagnosed with a hematologic malignancy during pregnancy had a 22-fold higher rate of severe maternal morbidity than those who did not have blood cancer, according to study results.Additional results showed no difference in 5-year OS between women diagnosed with a hematologic malignancy during pregnancy and those diagnosed in the year after pregnancy.
David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.
Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.
The FDA has extended the PDUFA date of the BLA for zenocutuzumab in NRG1-positive non–small cell lung cancer and pancreatic cancer.
The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.
Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.
Becker’s is proud to announce its 2024 list of hospitals and health systems recognized for excellence in oncology.
The latest news from the ACR Annual Meeting, including perspectives and interviews with leading researchers and clinicians, plus archives of past meetings.
An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue…
Big hospital systems are exploiting a Medicare loophole to charge older cancer patients thousands of dollars more per year for cancer treatment. Tell your members…
Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, according to new research.
